VP301 / Virtuoso Therap - LARVOL DELTA

CD38 x ICAM-1 Bispecific Antibody is a Novel Approach for Treating Multiple Myeloma and Lymphoma. (PubMed, Mol Cancer Ther) - "This bispecific antibody targets unique epitopes on CD38 and ICAM-1 on tumor cells with reduced red blood cell binding compared to the benchmark CD38 antibody daratumumab. Interestingly, combination of VP301 with the immunomodulatory drug, lenalidomide, led to synergistic anti-tumor growth activity in an in vivo efficacy study. In conclusion, the CD38 x ICAM-1 bispecific antibody VP301 demonstrated promising efficacy and specificity toward CD38+ and ICAM-1+ tumor cells and represents a novel approach for treating multiple myeloma and lymphoma."

IO biomarker • Journal • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • ICAM1

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Virtuoso BINco, Inc. | N=110 ➔ 2 | Trial completion date: Sep 2026 ➔ Jun 2023 | Recruiting ➔ Terminated | Trial primary completion date: Mar 2026 ➔ Jun 2023; Sponsor Decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Virtuoso BINco, Inc.

New P1 trial • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor

Multiple modes of action of the CD38 x ICAM-1 bispecific antibody (AACR 2022) - "Antibody against ICAM-1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody demonstrated potent tumor inhibition activities in in-vivo myeloma and lymphoma models. These studies suggested that CD38 x ICAM-1 bispecific antibody has multiple modes of action for treating lymphoma and multiple myeloma."

IO biomarker • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • ICAM1

Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Virtuoso Therapeutics...announced that it will present two posters highlighting the preclinical data from leading bispecific antibody programs at the American Associate for Cancer Research (AACR) 2022 Annual Meeting....Virtuoso bispecific antibodies confer greater tumor selectivity than monoclonal antibodies. This greater selectivity allows enhanced efficacy with strong effector functions, and improved safety profile."

Preclinical • Oncology

CD38 x ICAM1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma (ASH 2021) - "Antibody against ICAM1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody showed complete tumor inhibition in a rituximab-resistant lymphoma PDX model, whereas daratumumab only showed minimal efficacy. In conclusion, the CD38 x ICAM1 bispecific antibody demonstrated improved efficacy and specificity toward CD38 + and ICAM1 + tumor cells and represents a novel approach for treating multiple myeloma and lymphoma."

IO biomarker • Hematological Malignancies • Inflammatory Arthritis • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • ICAM1